Allogene Therapeutics, Inc.
ALLO- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001737287
In the last 90 days, Allogene Therapeutics, Inc. insiders filed 0 open-market purchases and 2 sales; 209 institutions reported holding it in 13F filings for Q2 2026, worth $652.0M in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 10, 2026
- $322.9M
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $111.7K in total
- 2
- 13F holdersQ2 2026, +1 vs. previous quarter
- 209
- 13F valueReported value at the end of Q2 2026
- $652.0M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $0
- −100.0% year over year
- Net income, FY2025
- -$190.9M
- No comparable prior period
- Free cash flow, FY2025
- -$149.6M
- No comparable prior period
- Revenue, Q3 FY2026
- $0
- No comparable prior period
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 51.3M
- Shares sold short
- Change
- −2.12M
- −4.0% vs. previous
- Days to cover
- 6.20
- At average daily volume
Superinvestors holding ALLO, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding ALLO at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Allogene Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Oct 23, 2026 (view filing)4:48 PM ET | Oct 21 | 2 days | Parker Geoffrey M.CHIEF FINANCIAL OFFICER | SSale | −36.3K | $1.34 | −$48.7K | −3.4%1.05M after | |
| Aug 25, 2026 (view filing)4:43 PM ET | Aug 21 | 4 days | Douglas Earl MartinSVP, General Counsel | SSale | −29.7K | $2.12 | −$63.0K | −5.7%488.3K after | |
| Apr 23, 2026 (view filing) | Apr 21 | 2 days | Yoshiyama AnnieSVP, Finance | SSale | −9.59K | $2.31 | −$22.1K | −7.1%124.5K after | |
| Apr 2, 2026 (view filing) | Mar 31 | 2 days | Beneski Benjamin MachinasSVP, Chief Technical Officer | SSale | −2.87K | $2.50 | −$7.17K | −1.4%195.3K after | |
| Mar 18, 2026 (view filing) | Mar 16 | 2 days | Beneski Benjamin MachinasSVP, Chief Technical Officer | SSale | −4.83K | $2.47 | −$11.9K | −2.4%198.2K after | |
| Mar 18, 2026 (view filing) | Mar 16 | 2 days | Chang David DPresident and CEO | SSale | −47.8K | $2.47 | −$118.0K | −0.9%5.15M after | |
| Mar 4, 2026 (view filing) | Mar 2 | 2 days | Beneski Benjamin MachinasSVP, Chief Technical Officer | SSale | −7.13K | $2.60 | −$18.5K | −3.4%203.0K after | |
| Feb 4, 2026 (view filing) | Feb 2 | 2 days | Beneski Benjamin MachinasSVP, Chief Technical Officer | SSale | −7.55K | $1.73 | −$13.1K | −3.5%210.2K after | |
| Feb 4, 2026 (view filing) | Feb 2 | 2 days | Chang David DPresident and CEO | SSale | −95.3K | $1.80 | −$171.5K | −1.8%5.19M after | |
| Feb 4, 2026 (view filing) | Feb 2 | 2 days | Parker Geoffrey M.CHIEF FINANCIAL OFFICER | SSale | −24.0K | $1.76 | −$42.2K | −1.9%1.25M after |
Top 10 13F holders, Q2 2026
See all 209 holdersThe largest institutional positions in Allogene Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 30,146,963 | $62.7M | 0.00% | +11,055,868+57.9% | Added |
| Pfizer Inc | 22,032,040 | $46.9M | 27.55% | 00.0% | Unchanged |
| Frazier Life Sciences Management, L.P. | 22,446,668 | $46.7M | 1.02% | +18,650,000+491.2% | Added |
| State Street Corp | 19,025,826 | $39.6M | 0.00% | +10,365,520+119.7% | Added |
| TPG GP A, LLC | 18,716,306 | $38.9M | 0.78% | 00.0% | Unchanged |
| Sio Capital Management, LLC | 13,323,431 | $27.7M | 4.75% | +13,323,431 | New |
| Primecap Management Co | 13,123,440 | $27.3M | 0.02% | +4,743,600+56.6% | Added |
| Vanguard Capital Management LLC | 12,166,636 | $25.3M | 0.00% | +5,245,286+75.8% | Added |
| FMR LLC | 12,009,043 | $25.0M | 0.00% | +10,419,213+655.4% | Added |
| Citadel Advisors LLC | 10,087,770 | $21.0M | 0.01% | +3,294,150+48.5% | Added |
Holders of 5% or more of ALLO
See all 3 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Allogene Therapeutics, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Pfizer Inc | 13D/A | 9.00%22.0M shares | – | Sep 17, 20214 filings | Feb 13, 2026 | SEC |
| BlackRock, Inc. | 13G/A | 6.70%23.2M shares | +1.40 ppfrom 5.30% | Oct 22, 20244 filings | Oct 27, 2026 | SEC |
| Frazier Life Sciences Public Fund, L.P. | 13G/A | 5.60%19.4M shares | +0.90 ppfrom 4.70% | Apr 23, 20262 filings | Aug 14, 2026 | SEC |